Figure 5: In vitro endocytosis of glyco-modified pertuzumab.
From: Glycoengineering of pertuzumab and its impact on the pharmacokinetic/pharmacodynamic properties
Cells were incubated with 10 μM FITC-asialofetuin in the presence of 1 μM glyco-modified pertuzumabs. After 60 min incubation, endocytosis was stopped and intracellular FITC-asialofetuin was extracted to measure the fluorescence intensity (A,B). Indicated gradient glyco-modified pertuzumabs were added in the presence of 100 nM FITC-asialofetuin in HepG2 (A) and L-02 (B). Data are representative of three independent experiments with similar results (n = 3). Fuc: fucose, SA: Sialic acid.
